Published literature varies widely on dosage regimens, with an emphasis on the importance of gradual dose selection under the direct support and monitoring of a medical doctor to assess clinical tolerance and individual response assessment
Although leg cramps are not listed as an official adverse effect in FDA prescribing information, understanding the potential indirect mechanismsincluding dehydration, electrolyte imbalances, and nutritional changescan help patients and clinicians address this symptom effectively while continuing therapy
as an oral communication at the 51st Annual Meeting of the European Association for the Study of Diabetes, Stockholm, Sweden, 1418 September 2015
[3] A 2018 follow-up study further characterized 5-Amino-1MQ in cell-based assays and reported the following selectivity profile against other methyltransferases and related enzymes at concentrations up to 600 M: no detectable inhibition of DNMT1, PRMT3, or NAMPT